- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02375737
Evaluating CVD Medication Adherence Program in Low SES (CVDMAT)
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The investigators propose to evaluate the implementation of a medication adherence program among patients who attend Duke Outpatient Clinic (DOC). It is anticipated that, among the providers' patient panels, at least 100 and up to 300 with CVD risk and poor CVD medication adherence (<0.08 medication possession ratio) will consent to the program.
Using procedures from the investigators previous studies, the investigators will identify potential patients from the EHR, and will identify a pool of potential patients using electronic health records, with the goal of administering the program to at least 100 patients. Patients will be mailed letters, signed by their own provider or medical director of DOC, requesting their participation in the programs. The RA will contact patients via telephone to explain the study, screen for eligibility, and determine what mode of administration individuals prefer to receive the program (SMS, IVR, or email).
The primary outcome will be that the effectiveness/impact of the proposed adherence program will be a 10% improvement in MPR and CVD outcomes (anticipate reducing SBP by 5 mmHg, Hgb a1c by 0.5%, LDL-C by 20 mg/dl).
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27705
- Duke University Health System Clinic
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Medicaid recipient (preferred); however the investigators will include those patients with other types of insurance or those who are uninsured
- Enrolled in Duke Outpatient Clinic for at least one year
- Outpatient diagnostic code for hypertension and/or hypercholesterolemia and/or diabetes
- Poorly controlled BP levels (>140/90) and/or LDL-C (>130mg/dl) and/or HbA1c of >8 within last 6 months
Exclusion Criteria:
- No access to cell phone
- Not proficient in English
- Nursing home/long-term care facility resident or receiving home health care
- Impaired hearing/ speech/ vision
- Participating in another trial (pharmaceutical or behavioral)
- Planning to leave the area in the next 12 months
- Pregnancy (or planning)
- Diagnosis of life-threatening disease with death probable within 1 year
- Active Diagnosis of psychosis or dementia (has been hospitalized in the last 30 days)
- Diagnosis of ESRD
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: m-health
Patients will receive text message, emails, and monthly phone calls
|
Patients will receive e-reminders via text message and email.
A message library that allows us to disseminate constant and reliable information has been created.
Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence.
In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Adherence to the program's intervention
Tidsramme: 6 months
|
It is measured as the proportion of technology or interventionist contacts responded to by a patient out of those received over the course of the intervention period.
This will be summarized descriptively by type of contact (technology vs. interventionist call) and subdivided by technology (SMS, email).
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Clinical effectiveness/impact of the program to pill refill adherence
Tidsramme: 6 months
|
This will be measured by pulling pill refill records of those patients who are enrolled.
The investigators anticipate an improvement of 10% on pill refill adherence.
|
6 months
|
Clinical effectiveness/impact on BP
Tidsramme: 6 months
|
This will be measured by assessing systolic BP values.
The investigators anticipate reducing SBP by 5 mmHg.
|
6 months
|
Clinical effectiveness/impact on A1C
Tidsramme: 6 months
|
This will be measured by assessing A1C values.
The investigators anticipate reducing Hgb A1c by 0.5%.
|
6 months
|
Clinical effectiveness/impact on cholesterol
Tidsramme: 6 months
|
This will be measured by assessing LDL-C levels in patients.
The goal is to reduce LDL-C levels by 20 mg/dl.
|
6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Hayden Bosworth, PhD, Duke University
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Pro00054572
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hypertensjon
-
University Hospital of CologneUkjentNAFLD; Hypertensjon, White-Coat Hypertension, Masked HypertensionTyskland
-
Karolinska InstitutetFullførtWhite Coat Hypertension
-
Clinical Hospital Centre ZagrebEuropean Society of HypertensionUkjentWhite Coat Hypertension | Blodtrykk | LivsstilsrisikoreduksjonIsrael, Hellas, Belgia, Tyskland, Armenia, Østerrike, Bulgaria, Kroatia, Tsjekkia, Estland, Italia, Libanon, Litauen, Nederland, Polen, Portugal, Romania, Serbia, Spania, Sverige, Ukraina, Storbritannia
-
Regional Hospital HolstebroFullførtSunn | White Coat Hypertension | Essensiell hypertensjonDanmark
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Aktiv, ikke rekrutterendeWhite Coat Hypertension | Hypertensjon, viktigForente stater
-
University of Alabama at BirminghamTroy UniversityFullførtHypertensjon | Hypertensjon, motstandsdyktig mot konvensjonell terapi | Ukontrollert hypertensjon | Hypertensjon, hvit pelsForente stater
-
PD Dr. Grégoire WuerznerSwiss National Science FoundationFullførtHypertensjon | Overvekt | White Coat Hypertension | Resistent hypertensjonSveits
-
University Hospital, ToursFullførtPTFE-dekkede stenter versus nakne stenter i TIPS (Transjugulær Intra-hepatisk Porto-systemisk shunt)Cirrhotic Portal HypertensionFrankrike
-
Sun Yat-sen UniversityFullførtHepatocellulært karsinom (HCC) | Cirrhotic Portal HypertensionKina
Kliniske studier på m-health
-
University of Texas Southwestern Medical CenterFullførtHjertesvikt med bevart ejeksjonsfraksjonForente stater
-
IRCCS Burlo GarofoloRekruttering
-
Universitas Muhammadiyah YogyakartaMinistry of Education Culture, Research and TechnologyHar ikke rekruttert ennåLivskvalitet | Kroniske nyresykdommer | Følelse av mestringsevne | M-helseIndonesia
-
Universidad del DesarrolloInstituto Milenio para Investigación en Depresión y Personalidad; Peñalolén...RekrutteringDepresjon, postpartum | Angstlidelser og symptomer | Mors oppførselChile
-
Prince of Songkla UniversityFullførtUnderstreke | Omsorgsbyrde | Traumatisk hjerneskadeThailand
-
Aga Khan UniversityHar ikke rekruttert ennåUnderernæring, barn | Underernæring, spedbarnPakistan
-
Goethe UniversityKing's College London; Radboud University Medical Center; Heidelberg University og andre samarbeidspartnereFullførtDepresjon | Overvekt | Attention-Deficit / Hyperactivity DisorderTyskland, Nederland, Spania, Storbritannia
-
Florida State UniversityUniversity of North Carolina, Chapel Hill; University of GeorgiaPåmelding etter invitasjonRisikoreduksjon for kardiovaskulær sykdomForente stater
-
IWK Health CentreHar ikke rekruttert ennå
-
Manan ShuklaFullførtAstma | Kronisk sykdomForente stater